Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 179-184

  Meiyanto, Edy ^a   Putri, Dyaningtyas Dewi Pamungkas ^a   Susidarti, Ratna Asmah ^a   Murwanti, Retno ^a   Sardjiman, ^a   Fitriasari, Aditya ^a   Husnaa, Ulfatul ^a   Purnomo, Hari ^a   Kawaichi, Masashi ^b  

^a GADJAH MADA UNIVERSITY   (Indonesia)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Curcumin and its analogues; HER2; MCF 7 Dox cells; NF kB

Indexed keywords

2- ((4-HYDROXY-3,5-DIMETHYLPHENYL)METHYLIDENE)-5-((3-METHOXY-4,5-DIMETHYLPHENYL)METHYLIDENE)CYCLOPENTAN-1-ONE; 2 ((4 HYDROXY 3,5 DIMETHYLPHENYL)METHYLIDENE) 5 ((3 METHOXY 4,5 DIMETHYLPHENYL)METHYLIDENE)CYCLOPENTAN 1 ONE; ANTINEOPLASTIC AGENT; CURCUMIN; DOXORUBICIN; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PENTAGAMAVUNON 0; PENTAGAMAVUNON-0; TRANSCRIPTION FACTOR RELA;

ARTICLE; CELL NUCLEUS; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; IC 50; MCF 7 CELL LINE; METABOLISM;

ANTINEOPLASTIC AGENTS; CELL NUCLEUS; CELL SURVIVAL; CURCUMIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; NF-KAPPA B; RECEPTOR, ERBB-2; TRANSCRIPTION FACTOR RELA;

EID: 84894075868     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.179     Document Type: Article

References (22)

1. Aggarwal BB, Kumar A, Bharti AC (2003). Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res, 23, 363-98.
2. Byun SS, Kim SW, Choi H, Lee C, Lee E (2005). Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int, 95, 1086-90.
3. Claeson P, Tuchinda P, Revtrakul V (1994). Naturally occuring 1,7-diarylheptanoids, J Indian Chem Soc, 71, 509-21.
4. Da'i M, Jenie UA, Supardjan AM, Kawaichi M, Meiyanto E (2007). T47D cells arrested at G2M and hyperploidy formation induced by a curcumin analogue, PGV-1, Indon. J Biotechnol, 12, 1005-12.
5. Da'i M, Supardjan AM, Meiyanto E, Jenie UA (2007). Isomers geometric and cytotoxic effect curcumin analogue PGV-0 and PGV-1 on T47D cells. Indonesian J Pharm, 18, 40-7.
6. Hanahan D, Weinberg RA (2011). The hallmark of cancer: The next generation. Cell, 100, 57-70.
7. Kiguchi K, Carbajal S, Chan K (2001). Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res, 61, 6971-6.
8. Kuttan PR, Bhanumathy P, Nirmala K, George GC (1985). Potential anticancer activity of turmeric (Curcuma longa), Cancer Lett, 29, 197-202.
9. Lutomsky J, Kedzia B, Debska W (1974). Effect of an alcohol extract and of active ingredients from Curcuma longa on bacteria and fungi. Planta Medica, 26, 9-19.
10. Mazumder A, Neamati N, Sunder S, et al (1997). Curcumin analogues with altered potencies against HIV-1 integrase as probes for biochemical mechanism of drug action. J Med Chem, 40, 3057-63.
11. Meiyanto E, Supardjan, Da'i M, Agustina D (2006). Antiproliferative effect of pentagamavunon-0 on T47D breast cancer cells. Med J Yarsi, 14, 11-5.
12. Meiyanto E, Supardjan, Da'i M, Agustina D (2007). Pentagamavunon-0 induces Apoptosis on T47D breast cancer cell line through caspase-3 activation. Med J Yarsi, 15, 75-9.
13. Nasiri M, Zarghami N, Koshki KN, et al (2013). Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev, 14, 3449-53.
14. Putri DDP, Sarmoko, Febriansah R, et al (2012). MCF-7 resistant doxorubicin are characterized by lamellipodia, strong adhesion on substrate and pgp overexpression. Indo J Can Chemoprev, 2, 304-8.
15. Ramprasad C, Sirrsi M (1957). Curcuma longa and bile secretion-quantitative changes in the bile constituents induced by sodium curcuminate. J Sci Industry Res, 16, 108-10.
16. Sardjiman (2000). Synthesis of Some New Series of Curcumin Analogues, Anti-Oxidative, Anti-Inflammatory, Anti-Bacterial Acitivities and Qualitative Structure-Activity-Relationship, Disertation, Gadjah Mada University.
17. Shankar TNB, Murthy VS (1979). Effect of turmeric (curcuma longa) fractions on the growth of some intestinal and pathogenic bacteria in vitro. Indian J Exp Biol, 17, 1363-6.
18. Sharma SC, Mukhtar H, Sharma SK, Krishnamurti CR (1972). Lipid peroxide formation in experimental inflammation. Biochem Pharmacol, 21, 1210-4.
19. Shishodia S, Majumdar S, Banerjee S, Aggarwal BB (2003). Ursolic acid inhibits nuclear factor-κBα kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res, 63, 4375-83.
20. Srimal RC, Dhawan BN (1973). Pharmacology of diferuloyl methane (curcumin) a non steroid anti-inflamatory agent. J Pharm Pharmac, 25, 447-52.
21. Vadlamudi R, Mandal M, Adam L, et al (1999). Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene, 18, 305-14.
22. Vora T, de Azambuja E, Awada A, Piccart M (2009). Novel therapeutics in breast cancer-looking to the future. Update Cancer Therapeutics, 3, 189-205.